TheraPanacea receives 2.5 million euros non-dilutive grant from the EU Horizon 2020 EIC Accelerator. This funding will enable them to reinvent cancer care by coupling the latest advances in AI with the latest state-of-the-art MR-Linac technology.

Radiotherapy is one of the most widely-used treatments against cancer, with 60% of European cancer patients treated. However, current treatment planning software for radiotherapy heavily relies on toxic CT-imaging which leads to undesirable toxic radiation of patients with no option of plan adjustment during therapy and non-optimal clinical outcomes. This grant and collaboration with leading French and European cancer research centers including Gustave Roussy (France), Institut de Cancérologie de Montpellier (France) and Tübingen Universität (Germany), will accelerate the commercialization of the ART-AI Platform, the first fully-adaptive and AI-powered treatment planning suite that can enable automated and non-toxic MR-guided radiotherapy.

UE cofunded Therapanacea

This unique platform is the first TPS that couples real-time MR image analysis with LINAC infrastructure, and delivers tumour annotation and dose estimation, enabling ‘on-the-fly’ radiotherapy treatment planning using deep and reinforcement learning, and AI-powered real-time simulation in one software suite. The plan is adjusted according to real-time changes in patient anatomy. The main advantages offered by our product is the leveraging of MR benefits that lead to drastic reduction in treatment toxicity and in radiotherapy duration. To facilitate clinical radiotherapy workflow, the ART-AI platform offers a web-based solution for the radiotherapy treatment planning interface that can be directly incorporated into the hospital’s existing IT infrastructure and accessed directly through cloud solutions.